An advertisement may cite a real paper and still invite an interpretation the paper never tested. The missing step is often the bridge between the research and the offer. Reading that bridge carefully is more useful than accepting every linked citation as validation or dismissing every commercial claim because it is commercial.
Identify the object of the claim
Start by naming what the sentence says is better: a medicine, a dose, a behavioral program, a pharmacy, a subscription or the whole package. These are different objects. A trial can study one without evaluating the others. If a provider places a trial result beside its logo, ask whether the provider itself participated in the research and which component was actually studied.
Find the product in the original source
The study methods should specify the intervention sufficiently to understand the comparison. Ingredient name alone may leave formulation, route, strength, schedule and accompanying care unclear. FDA explains that compounded medicines do not undergo the same premarket approval review as approved products. A citation to an approved-product trial does not eliminate that distinction. [Compounded-product status]
This does not mean a patient-specific compounded medicine can never have a medical role. It means the evidence statement must match what has been established. Ask the prescribing professional to explain the reason for the proposed preparation and the limits of the available evidence for your situation.
Track the people included in the result
Look for the number enrolled and the number represented in the analysis. A result restricted to people who completed a program may answer a different question from the result for everyone who started it. People who keep attending, reporting or paying can differ from those who leave. Without knowing the design and handling of missing information, a striking average is difficult to interpret.
Separate association from an intervention test
People who use a feature more often may also differ in motivation, access, health or support. An association between engagement and an outcome does not by itself prove that the feature caused the difference. Random assignment can address some of these alternative explanations, but even a randomized study has boundaries around population, comparator and follow-up. SELECT, for example, reports a specified intervention against placebo in a defined cardiovascular population; it is not a comparison of subscription services. [Original randomized trial; abstract reviewed]
Keep a short claim ledger
For a consequential purchase, record the advertised sentence, the linked source, the actual studied intervention and the remaining gap. Ask the service to explain that gap without replacing the source with another testimonial. A useful answer may be modest: a feature is available, while its effect has not been separately measured.
The point is not to demand a trial for every administrative feature. It is to apply the right standard to the claim being made. A clear billing policy can be evaluated as a policy. A clinical superiority claim needs appropriate clinical evidence. Keeping those questions distinct makes both comparisons more honest.
Source notes
Checked October 5, 2026. Provider pages document advertised terms. Study summaries identify the scope of our review.
- Lincoff et al. — SELECT cardiovascular outcomes trialOriginal randomized trial; abstract reviewed
- FDA — compounding questions and answersCompounded-product status
- FDA — concerns with unapproved GLP-1 drugsRegulatory and safety context